

QUANTUM HEALTHCARE LIMITED
(Company Registration No. 202218645W)
(Incorporated in Singapore)

UPDATE ON USE OF PLACEMENT PROCEEDS

1. INTRODUCTION

The board of directors (the “**Board**”) of Quantum Healthcare Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the announcements dated 22 September 2025, 24 September 2025, 20 October 2025, 21 November 2025 and 28 November 2025, and wishes to update shareholders of the Company (the “**Shareholders**”) on the use of proceeds relating to the share placement of 2,727,272,800 ordinary shares in the capital of the Company that raised placement proceeds of S\$3,000,000.08 (the “**Placement Proceeds**”).

2. UPDATE ON USE OF PROCEEDS

As previously announced by the Company on 22 September 2025, up to S\$1,000,000 of the Placement Proceeds was set aside to meet the Group’s working capital requirements while up to S\$2,000,000 of the Placement Proceeds was set aside to fund suitable acquisition targets and M&A opportunities within the MedTech sector (including transaction expenses related to such acquisitions and M&A).

As at the date of this announcement, S\$855,000 of the Placement Proceeds set aside to meet the Group’s working capital requirements has been utilised, breakdown of which is as presented below, while the S\$2,000,000 Placement Proceeds set aside to fund suitable acquisition targets and M&A opportunities within the MedTech sector remains wholly unutilised.

The breakdown for the S\$855,000 utilised for the Group’s working capital requirements is as follows:

Directors’ fees – S\$93,000
Salaries – S\$12,000
Professional fees – S\$650,000
Administrative expenses – S\$100,000

Having reviewed and considered the Group’s projected funding requirements, capital allocation priorities as well as M&A opportunities currently being assessed by the Company, the Board has decided to re-allocate use of the Placement Proceeds in the following manner to better support the Group’s strategic objectives and optimise the deployment of available financial resources:

Use of Placement Proceeds	Original Allocation	Balance Available to-date	Revised Allocation	Balance Available to-date following revised allocation	% of Placement Proceeds for Revised Allocation
To meet the Group’s anticipated working capital requirement for the purpose of meeting general overheads and other operating expenses of the	S\$1,000,000	S\$145,000	S\$1,500,000	S\$645,000	50%

Group (such as rent, salaries, administrative expenses, professional fees)					
To fund suitable acquisition targets and M&A opportunities within the MedTech sector (including transaction expenses related to such acquisitions and M&A).	S\$2,000,000	S\$2,000,000	S\$1,500,000	S\$1,500,000	50%
Total	S\$3,000,000	S\$2,145,000	S\$3,000,000	S\$2,145,000	100%

Further, the Board has decided to advance or place an amount of S\$600,000 from the unutilised Placement Proceeds set aside for acquisition and M&A opportunities (the “**Promissory Note Amount**”) with Aios Bio Sciences Pte Ltd (“**Aios Bio Sciences**”), for which Aios Bio Sciences has issued a promissory note (“**Promissory Note**”) to the Company, on the terms as set out below:

Terms of Promissory Note

Principal Amount: S\$600,000

Interest: 12% per annum

Repayment: On demand

Security: In consideration of the Company agreeing to advance or place the Promissory Note Amount with Aios Bio Sciences, Robin Ng Zhi Peng (“**Robin Ng**”), who is a director and shareholder owning approximately 25.2% of the total issued and paid-up share capital of Aios Bio Sciences, has:

- (a) issued a personal guarantee in favour of the Company (the “**Personal Guarantee**”) where he has agreed to guarantee the repayment or payment of the Promissory Note Amount as guarantor and principal obligor; and
- (b) granted a share pledge in respect of 10% of the total issued and paid-up share capital of Aios Bio Sciences (the “**Pledged Shares**”) in favour of the Company, where the Pledged Shares are pledged as security for the obligations of Aios Bio Sciences under the Promissory Note and Robin Ng under the Personal Guarantee.

3. RATIONALE

Since the receipt of the Placement Proceeds, the Company has been actively exploring various options for potential acquisition targets and M&A opportunities. However, the Board does not expect to be able to enter into definitive agreement(s) or to complete any such contemplated transaction(s) or corporate action(s), and accordingly to utilise the Placement Proceeds set aside

for such purpose on an immediate basis, after taking into consideration *inter alia*, the legal and financial due diligence and other due process involved.

In the interim, the Company has not been able to identify short-term deposit or investment with banks or financial institutions that earns a comparable return on such unutilised Placement Proceeds. The advance or placing of the Promissory Note Amount with Aios Bio Sciences will allow the Company to earn a higher return on a temporary or short-term basis, pending deployment of such funds for its intended purpose.

Aios Bio Sciences is a private exempt company incorporated in Singapore with an issued and paid-up capital of S\$3,000,000, and is engaged in the manufacture of medical disposables and surgical supplies, and the opportunity for the Company to advance or place the Promissory Note to Aios Bio Sciences on the terms of the Promissory Note came about in the course of discussions on potential collaboration or other opportunities between the parties.

4. INTEREST OF THE DIRECTORS AND CONTROLLING SHAREHOLDERS

None of the Directors has, and to the best of the Directors' knowledge, there are no controlling shareholders of the Company who have, any interest, direct or indirect, in the advance of the Promissory Note Amount, save in respect of their shareholdings (if any) in the Company.

By Order of the Board

QUANTUM HEALTHCARE LIMITED

Gian Siong Lin Jimmy
Executive Chairman and Chief Executive Officer
23 June 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.